This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reinholz, G. G. Articles by Spelsberg, T. C. Search for Related Content PubMed PubMed Citation Articles by Reinholz, G. G. Articles by Spelsberg, T. C.

Bisphosphonates Directly Regulate Cell Proliferation, Differentiation, and Gene Expression in Human Osteoblasts¹

Departments of Biochemistry and Molecular Biology [G. G. R., B. G., L. P., E. S. S., M. S., T. C. S.] and Oncology [J. N. I.], Mayo Clinic, Rochester, Minnesota 55905

Bisphosphonates are widely used clinically to treat bone diseases in which bone resorption is in excess. However, the mechanism of bisphosphonate action on bone is not fully understood. Studies of direct action of bisphosphonates on bone have been limited mainly to their effects on bone-resorbing osteoclast cells, with implications that some activity may be mediated indirectly through paracrine factors produced by the bone-forming osteoblast cells. Little is known about the direct effects of bisphosphonates on osteoblasts. In this report, the direct actions of several bisphosphonates on cell proliferation, gene expression, and bone formation by cultured human fetal osteoblasts were examined. Osteoblast cell proliferation was decreased, and cytodifferentiation was increased in a dose-dependent manner in cultures treated with the bisphosphonate pamidronate. In addition, pamidronate treatment increased total cellular protein, alkaline phosphatase activity, and type I collagen secretion in osteoblasts. Consistent with the above-mentioned findings, the rate of bone formation was also increased in osteoblasts cultured with pamidronate. The actions of two other bisphosphonates, the weak-acting etidronate and the potent new analogue zoledronate, were also compared with the action of pamidronate on proliferation of immortalized human fetal osteoblast (hFOB) cells and rate of bone formation. Pamidronate and zoledronate decreased hFOB cell proliferation with equal potency, whereas etidronate decreased proliferation only at much higher concentrations. Studies comparing EDTA and etidronate indicate that etidronate may act indirectly on the hFOB cells by reducing free divalent ion concentrations, whereas pamidronate and zoledronate appear to act on the hFOB cells by a direct action. Both pamidronate and zoledronate increase hFOB cell bone formation, whereas no increase is observed with etidronate and EDTA. Taken together, these observations strongly suggest that treatment with pamidronate or zoledronate enhances the differentiation and bone-forming activities of osteoblasts.

This article has been cited by other articles:

				A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]

				L. Tauchmanova, A. Colao, G. Lombardi, B. Rotoli, and C. Selleri REVIEW: Bone Loss and Its Management in Long-Term Survivors from Allogeneic Stem Cell Transplantation J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4536 - 4545. [Abstract] [Full Text] [PDF]

				J. C. Buckland-Wright, E. A. Messent, C. O. Bingham III, R. J. Ward, and C. Tonkin A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients Rheumatology, February 1, 2007; 46(2): 257 - 264. [Abstract] [Full Text] [PDF]

				A. Boyde Jaw Bone Necrosis and Bisphosphonates: Microanatomical Questions IBMS BoneKEy, September 1, 2006; 3(9): 19 - 23. [Abstract] [Full Text] [PDF]

				G A Clines and T A Guise Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone Endocr. Relat. Cancer, September 1, 2005; 12(3): 549 - 583. [Abstract] [Full Text] [PDF]

				B. Peter, P.-Y. Zambelli, J. Guicheux, and D. P. Pioletti The effect of bisphosphonates and titanium particles on osteoblasts: AN IN VITRO STUDY J Bone Joint Surg Br, August 1, 2005; 87-B(8): 1157 - 1163. [Abstract] [Full Text] [PDF]

				M. Yamauchi, T. Yamaguchi, H. Kaji, T. Sugimoto, and K. Chihara Involvement of calcium-sensing receptor in osteoblastic differentiation of mouse MC3T3-E1 cells Am J Physiol Endocrinol Metab, March 1, 2005; 288(3): E608 - E616. [Abstract] [Full Text] [PDF]

				L. Tauchmanova, P. Ricci, B. Serio, G. Lombardi, A. Colao, B. Rotoli, and C. Selleri Short-Term Zoledronic Acid Treatment Increases Bone Mineral Density and Marrow Clonogenic Fibroblast Progenitors after Allogeneic Stem Cell Transplantation J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 627 - 634. [Abstract] [Full Text] [PDF]

				S P Conway, B Oldroyd, A Morton, J G Truscott, and D G Peckham Effect of oral bisphosphonates on bone mineral density and body composition in adult patients with cystic fibrosis: a pilot study Thorax, August 1, 2004; 59(8): 699 - 703. [Abstract] [Full Text] [PDF]

				H L Neville-Webbe and R E Coleman The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia Palliative Medicine, September 1, 2003; 17(6): 539 - 553. [Abstract] [PDF]

				H. Tokuda, A. Harada, K. Hirade, H. Matsuno, H. Ito, K. Kato, Y. Oiso, and O. Kozawa Incadronate Amplifies Prostaglandin F2{alpha}-induced Vascular Endothelial Growth Factor Synthesis in Osteoblasts: ENHANCEMENT OF MAPK ACTIVITY J. Biol. Chem., May 23, 2003; 278(21): 18930 - 18937. [Abstract] [Full Text] [PDF]

				S. L. Elkin, S. Vedi, S. Bord, N. J. Garrahan, M. E. Hodson, and J. E. Compston Histomorphometric Analysis of Bone Biopsies from the Iliac Crest of Adults with Cystic Fibrosis Am. J. Respir. Crit. Care Med., December 1, 2002; 166(11): 1470 - 1474. [Abstract] [Full Text] [PDF]

				J F Van Offel, A J Schuerwegh, C H Bridts, W J Stevens, and L S De Clerck Effect of bisphosphonates on viability, proliferation, and dexamethasone-induced apoptosis of articular chondrocytes Ann Rheum Dis, October 1, 2002; 61(10): 925 - 928. [Abstract] [Full Text] [PDF]

				H. Sowa, H. Kaji, T. Yamaguchi, T. Sugimoto, and K. Chihara Activations of ERK1/2 and JNK by Transforming Growth Factor beta Negatively Regulate Smad3-induced Alkaline Phosphatase Activity and Mineralization in Mouse Osteoblastic Cells J. Biol. Chem., September 20, 2002; 277(39): 36024 - 36031. [Abstract] [Full Text] [PDF]

				S. S. Virtanen, H. K. Vaananen, P. L. Harkonen, and P. T. Lakkakorpi Alendronate Inhibits Invasion of PC-3 Prostate Cancer Cells by Affecting the Mevalonate Pathway Cancer Res., May 1, 2002; 62(9): 2708 - 2714. [Abstract] [Full Text] [PDF]

				I. R. Reid, J. P. Brown, P. Burckhardt, Z. Horowitz, P. Richardson, U. Trechsel, A. Widmer, J.-P. Devogelaer, J.-M. Kaufman, P. Jaeger, et al. Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density N. Engl. J. Med., February 28, 2002; 346(9): 653 - 661. [Abstract] [Full Text] [PDF]

				Bisphosphonates for osteoporosis DTB, September 1, 2001; 39(9): 68 - 72. [Abstract] [Full Text] [PDF]